GemOx方案治疗晚期复发转移卵巢癌的疗效观察

《GemOx方案治疗晚期复发转移卵巢癌的疗效观察》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、GemOx方案治疗晚期复发转移卵巢癌的疗效观察【摘要】目的：探讨GemOx方案(吉西他滨联合奥沙利铂)治疗晚期复发转移卵巢癌的疗效及不良反应。方法：共入组22例患者,其中铂类敏感复发转移12例，铂类耐药复发转移10例。所有患者均予吉西他滨1000mg/m2第1,8天静脉给药;奥沙利铂130mg/m2，第1天静脉给药。3周为1周期，每个患者至少接受2周期化疗用药。每2个周期后评价疗效、临床受益反应及不良反应。结果：共完成82个化疗周期，可评价疗效的21例，有效率为31.8%，铂类敏感患者中，有效率为41.7%，铂类耐药

2、为20.0%;临床受益反应率为57.1%;主要毒性反应为骨髓抑制和神经毒性,白细胞减少15例(68.2%)，血小板减少16例(72.7%)，神经毒性、感觉异常达71.4%。结论：GemOx方案治疗晚期复发转移卵巢癌患者是有效的,毒性反应可以耐受，生存质量明显提高。【关键词】海南省人民医院肿瘤内科，海南海口570311EffectofgemcitabineandoxaliplatinonrecurrentadvancedovariancarcinomaWANGLin,XIEXianhe,MAIZefeng,WANG

3、Wei,XINGXuehua(DepartmentofOncology,People’sHospitalofHainanProvinceHaikou570311,China)[ABSTRACT]Objective:Toevaluatetheeffectsofgemcitabineandoxaliplatin(GemOx)onrecurrentadvancedovariancarcinomaanditsadversereactions.Methods:Atotalof22patientswithrecur

4、rentadvancedovariancarcinomawereenrolled,including12patientsofplatinumsensitiveand10patientsofplatinumresistant.Allpatientsweretreatedwithgemcitabine1000mg/m2intravenouslyat1,8daysandoxaliplatin130mg/m2intravenouslyatfirstday;3weekswas1cycle;eachpatientreceiv

5、edatleast2cyclesofchemotherapy.Efficacy,clinicalbenefitresponseandadversereactionswereevaluatedeverytwocycles.Results:Atotalof82cyclesofchemotherapywerecompleted;21casesreceivedevaluationofefficacy,andtheeffectiveratewas31.8%;theeffectiverateforplatinumsensiti

6、veandplatinumresistantpatientswas41.7%and20.0%respectively;clinicalbenefitresponseratewas57.1%;themaintoxicitywasbonemarrowdepressionandneurologicaltoxicity,15casesoccurredleukopenia(68.2%),16casesoccurredthrombocytopenia(72.7%),71.4%patientsoccurredneurotoxic

7、ityandsensoryabnormalities.Conclusion:TreatmentofrecurrentadvancedovariancancerwithGemOxiseffective,thetoxicityistolerable,andthequalityoflifewasimprovedmarkedly.[KEYWORDS]Ovariantumor;Cancer;Drugtherapy;Gemcitabine;Oxaliplatin晚期复发转移的卵巢癌2线化疗的疗效较低，尤其是铂类耐药复发的化疗目前

8、仅是短期症状姑息治疗,疗效差,存活期短,仅1年左右。选择药物时要特别关注药物毒性及患者生活质量。使用吉西他滨联合奥沙利铂方案治疗22例晚期复发转移卵巢癌,取得较好效果,现报道如下。1资料与方法1.1临床资料2005～2008年收治的22例晚期复发转移卵巢癌患者，年龄30～76岁，中位年龄57岁;其中，肺转移15例，肝转移14例，骨转移10例，胸